Video

Will Biosimilars Impact the Cost of Specialty Drugs?

Author(s):

Davy James, Managing Editor

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Related Videos
Related Content
NCCN Flash Update: Changes to Colon Cancer Guidelines, Version 3.2025
April 25th 2025

NCCN Flash Update: Changes to Colon Cancer Guidelines, Version 3.2025

Alana Hippensteele, Lead Editor
Antibody Drug Conjugates and Breast Cancer: Insights from a Pharmacy Times Peer Exchange
April 14th 2025

Antibody Drug Conjugates and Breast Cancer: Insights from a Pharmacy Times Peer Exchange

Alexandra Gerlach, Associate Editor
Las Vegas strip, Aerial view
April 25th 2025

Asembia's AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Gout tophus, photomicrograph showing amorphous, eosinophilic material with a foreign-body giant cell reaction and inflammation
April 25th 2025

JAK1 Inhibitor NS-229 Granted FDA Orphan Drug Designation to Treat Allergic Autoimmune Condition

Luke Halpern, Assistant Editor
3D visualization of breast cancer cell metastasis | Image Credit: © freshidea - stock.adobe.com
April 25th 2025

Pyrotinib-Based Therapy May Improve Survival in Patients With HER2+ Breast Cancer and Liver Metastases

Alexandra Gerlach, Associate Editor